{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:16:37Z","timestamp":1791497797372,"version":"4.3.4"},"reference-count":100,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Inflammatory bowel disease (IBD), comprising Crohn\u2019s disease (CD) and ulcerative colitis (UC), represents a significant challenge in gastroenterology due to its chronic nature, unpredictable course, and impact on patients\u2019 quality of life. The therapeutic landscape for IBD has evolved significantly with the advent of biologic agents targeting specific immune pathways. However, limitations, including partial efficacy, side effects, and development of resistance, highlight the ongoing need for innovative treatment approaches. This review explores emerging therapies in IBD, including novel biologics, small molecules, microbiome-based therapies, and gene and stem cell therapies. The article summarizes their mechanisms of action, clinical efficacy, safety profiles, and potential future directions in IBD management. Methods: This comprehensive narrative review synthesizes current knowledge and emerging developments in inflammatory bowel disease (IBD) therapeutics. Literature was identified through targeted selection of high-quality sources, including pivotal randomized controlled trials, systematic reviews and meta-analyses, regulatory approval documents, and clinical practice guidelines from major gastroenterology societies. Emphasis was placed on recent publications (2020\u20132024) to capture the rapidly evolving therapeutic landscape, with particular attention to FDA\/EMA-approved therapies and promising late-stage investigational agents. Sources were prioritized based on clinical relevance, study quality, and regulatory status. This narrative approach was selected to provide comprehensive coverage of diverse therapeutic modalities spanning conventional treatments to cutting-edge techniques, including biologics, small molecules, microbiome-based therapies, gene therapy, and stem cell treatments. The review acknowledges the inherent limitations of non-systematic literature selection while prioritizing clinical utility and educational value for healthcare providers managing IBD patients in contemporary practice.<\/jats:p>","DOI":"10.3390\/jcm14176119","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T12:25:57Z","timestamp":1756470357000},"page":"6119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Emerging Therapies in Inflammatory Bowel Disease: A Comprehensive Review"],"prefix":"10.3390","volume":"14","author":[{"given":"John K.","family":"Appiah","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA 18711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Hayat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA 18711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2072-9704","authenticated-orcid":false,"given":"Nikita","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA 18711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richeal","family":"Asante","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA 18711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evans","family":"Donneyong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tamale Teaching Hospital, Tamale NT2701, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-0434","authenticated-orcid":false,"given":"Muhammad U.","family":"Haider","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA 18711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Geisinger Health System, Danville, PA 18711, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Advent Health, Orlando, FL 32803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Maimonides Medical Center, New York, NY 11219, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_2","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators (2020). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 5, 17\u201330."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/ibd\/izaa081","article-title":"The Cost of Inflammatory Bowel Disease: An Initiative from the Crohn\u2019s & Colitis Foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ajg.2017.97","article-title":"Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases","volume":"112","author":"Benchimol","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","first-page":"22529","article-title":"The epidemiology and risk factors of inflammatory bowel disease","volume":"8","author":"Ye","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-Cell Analysis of Crohn\u2019s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1053\/j.gastro.2021.02.056","article-title":"Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients with Gastrointestinal Symptoms","volume":"160","author":"Livanos","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_10","first-page":"1538","article-title":"The role of post-infectious functional gastrointestinal disorders and inflammatory bowel disease in the COVID-19 pandemic","volume":"159","author":"Brennan","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: Clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: Loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Chowers","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target","volume":"110","author":"Sandborn","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/apt.14510","article-title":"Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis","volume":"47","author":"Waljee","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2018.05.039","article-title":"Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn\u2019s disease","volume":"155","author":"Dulai","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10620-014-3350-9","article-title":"Environmental risk factors for inflammatory bowel diseases: A review","volume":"60","author":"Ananthakrishnan","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vebr, M., Pomaha\u010dov\u00e1, R., S\u00fdkora, J., and Schwarz, J. (2023). A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123229"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_22","first-page":"339","article-title":"Environmental risk factors for inflammatory bowel disease","volume":"6","author":"Molodecky","year":"2010","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Narula, N., Wong, E.C.L., Dehghan, M., Mente, A., Rangarajan, S., Lanas, F., Lopez-Jaramillo, P., Rohatgi, P., Lakshmi, P.V.M., and Varma, R.P. (2021). Association of ultra-processed food intake with risk of inflammatory bowel disease: Prospective cohort study. BMJ, 374.","DOI":"10.1136\/bmj.n1554"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/ibd\/izy060","article-title":"The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn\u2019s Disease\u2013Like Ileitis","volume":"24","author":"Harding","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ni.2534","article-title":"Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues","volume":"14","author":"Bernink","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41590-018-0298-5","article-title":"Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation","volume":"20","author":"Zundler","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","article-title":"Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases","volume":"104","author":"Frank","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut Microbiota in Patients with Irritable Bowel Syndrome\u2014A Systematic Review","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Arze","year":"2019","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: Management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn\u2019s disease: Systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update","volume":"105","author":"Relling","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: Practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved Long-term Outcomes of Patients with Inflammatory Bowel Disease Receiving Proactive Compared with Reactive Monitoring of Serum Concentrations of Infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_41","first-page":"400","article-title":"Long-term Efficacy of Vedolizumab for Ulcerative Colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn\u2019s Disease: The IM-UNITI Trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Olsen","year":"2017","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Jefremow, A., and Neurath, M.F. (2023). Novel small molecules in IBD: Current state and future perspectives. Cells, 12.","DOI":"10.3390\/cells12131730"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: First- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41575-019-0102-5","article-title":"Big data in IBD: A look into the future","volume":"16","author":"Olivera","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients with Crohn\u2019s Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients with Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"Dubinsky","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","article-title":"New treatment options for inflammatory bowel diseases","volume":"53","author":"Verstockt","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/gutjnl-2016-312297","article-title":"Antibiotics as deep modulators of gut microbiota: Between good, bad and ugly","volume":"65","author":"Ianiro","year":"2016","journal-title":"Gut"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients with Ulcerative Colitis","volume":"321","author":"Costello","year":"2019","journal-title":"JAMA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ecco-jcc\/jjx063","article-title":"Faecal microbiota transplantation for inflammatory bowel disease: A systematic review and meta-analysis","volume":"11","author":"Paramsothy","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/ibd\/izac135","article-title":"Efficacy of Fecal Microbiota Transplantation in the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials","volume":"29","author":"Chehade","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s10620-018-5396-6","article-title":"Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose","volume":"64","author":"Allegretti","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sokol, H., Landman, C., Seksik, P., Berard, L., Montil, M., Nion-Larmurier, I., Bourrier, A., Le Gall, G., Lalande, V., and De Rougemont, A. (2020). Fecal microbiota transplantation to maintain remission in Crohn\u2019s disease: A pilot randomized controlled study. Microbiome, 8.","DOI":"10.1186\/s40168-020-0792-5"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.15330","article-title":"Systematic review with meta-analysis: Efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome","volume":"50","author":"Ianiro","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/apt.16148","article-title":"Systematic review: The global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020","volume":"53","author":"Marcella","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/sj.gt.3302013","article-title":"Gene transfer approaches for the treatment of inflammatory bowel disease","volume":"10","author":"Wirtz","year":"2003","journal-title":"Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2011.02.046","article-title":"Recent insights into the genetics of inflammatory bowel disease","volume":"140","author":"Cho","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4291\/wjgp.v2.i6.114","article-title":"Gene and cell therapy based treatment strategies for inflammatory bowel diseases","volume":"2","author":"Majowicz","year":"2011","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nbt.4222","article-title":"Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria","volume":"36","author":"Isabella","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: From concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1097\/MIB.0000000000000543","article-title":"Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease","volume":"21","author":"Dave","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/gut.2008.168534","article-title":"Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis","volume":"58","author":"Anderson","year":"2009","journal-title":"Gut"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2017.12.020","article-title":"ADMIRE CD Study Group Collaborators. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn\u2019s disease","volume":"154","author":"Colombel","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","article-title":"A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn\u2019s Disease Refractory to Biologic Therapy","volume":"12","author":"Forbes","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ibd\/izz215","article-title":"Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn\u2019s Fistulas","volume":"26","author":"Lightner","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_85","first-page":"313","article-title":"Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn\u2019s disease: Results from a multicenter phase I\/IIa clinical trial","volume":"28","author":"Alba","year":"2012","journal-title":"Int. J. Color. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/gut.2010.214841","article-title":"Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn\u2019s disease","volume":"60","author":"Ciccocioppo","year":"2011","journal-title":"Gut"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/intimm\/dxy065","article-title":"Recent progress in organoid culture to model intestinal epithelial barrier functions","volume":"31","author":"Nakamura","year":"2019","journal-title":"Int. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMp1613723","article-title":"Clarifying stem-cell therapy\u2019s benefits and risks","volume":"376","author":"Marks","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_90","first-page":"3323","article-title":"An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis","volume":"96","author":"Lewis","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic, Radiologic, and Histologic Healing with Vedolizumab in Patients with Active Crohn\u2019s Disease","volume":"157","author":"Danese","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Pavlidis, P., Tsakmaki, A., Pantazi, E., Li, K., Cozzetto, D., Bell, J.D., Yang, F., Lo, J.W., Alberts, E., and Sa, A.C.C. (2022). Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nat. Commun., 13.","DOI":"10.1038\/s41467-022-33331-8"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2016.11.024","article-title":"Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: A nationwide Danish cohort study","volume":"15","author":"Singh","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_94","first-page":"123","article-title":"Prevalence and clinical implications of anti-drug antibody formation to infliximab and adalimumab in patients with inflammatory bowel disease","volume":"30","author":"Johnston","year":"2025","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_95","first-page":"669","article-title":"Current and emerging biologics for ulcerative colitis","volume":"15","author":"Kim","year":"2021","journal-title":"Gut and Liver"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn\u2019s disease: A multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","article-title":"Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: Efficacy and safety from a phase IIa randomised multicentre study","volume":"64","author":"Reinisch","year":"2015","journal-title":"Gut"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","article-title":"The Treatment-Naive Microbiome in New-Onset Crohn\u2019s Disease","volume":"15","author":"Gevers","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/apt.13460","article-title":"A validated web-based tool to display individualised Crohn\u2019s disease predicted outcomes based on clinical, serologic and genetic variables","volume":"43","author":"Siegel","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:17Z","timestamp":1760034917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":100,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14176119"],"URL":"https:\/\/doi.org\/10.3390\/jcm14176119","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}